Innovation in Genetic Medicines

We develop precision nucleic acid therapies addressing key clinical unmet needs through strategic development partnerships.

Pipeline/Partnership
Oncology
COVID-19 DNA Vaccines
Age-related Diseases
Program
Partner
Discovery
Screening
Preclinical
Phase 1
Phase 2
Phase 3
Internal
Undisclosed
Undisclosed
Vaccines
8 Undisclosed programs
Covigenix - VAX-001 Spike protein
Covigenix - VAX-002 Multiple epitopes
OSX-002: Immuno-oncology gene therapy
OncoSenX
OSX-001: p53-targeted suicide gene therapy
OncoSenX
Atherosclerosis
Senolytic
REPAIR Biotechnologies
OISIN Biotechnologies
3 undisclosed programs
Undisclosed
Metastasis
CIHR, NRC IRAP
NRC IRAP
Entos Pharmaceuticals
Unit 4550, 10230 Jasper Avenue
Edmonton, Alberta, Canada
T5J 4P6

Email: info@entospharma.com
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.